ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
71.95
+0.17 (0.24%)
At close: Aug 1, 2025, 4:00 PM
71.93
-0.01 (-0.02%)
After-hours: Aug 1, 2025, 7:57 PM EDT
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 4.01M EUR in the half year ending December 31, 2024, with 78.20% growth. This brings the company's revenue in the last twelve months to 10.59M, up 128.98% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
10.59M EUR
Revenue Growth
+128.98%
P/S Ratio
466.46
Revenue / Employee
153,449 EUR
Employees
69
Market Cap
5.34B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ABVX News
- 5 days ago - Abivax Announces Closing of $747.5 Million Public Offering - GlobeNewsWire
- 9 days ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) - GlobeNewsWire
- 9 days ago - Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst - Seeking Alpha
- 9 days ago - Abivax announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewsWire
- 9 days ago - Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares - GlobeNewsWire
- 10 days ago - Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewsWire
- 10 days ago - Abivax Announces Launch of Public Offering - GlobeNewsWire
- 10 days ago - Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity - Seeking Alpha